var data={"title":"Guanfacine: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Guanfacine: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6297?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=guanfacine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Guanfacine: Patient drug information&quot;</a> and <a href=\"topic.htm?path=guanfacine-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Guanfacine: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178166\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Intuniv;</li>\n      <li>Tenex [DSC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21313111\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Intuniv XR</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178189\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Alpha<sub>2</sub>-Adrenergic Agonist;</li>\n      <li>\n        Antihypertensive</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178170\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Hypertension:</b> Immediate release: Oral: 1 mg once daily at bedtime, may increase if needed after 3 to 4 weeks of therapy to 2 mg daily at bedtime. <b>Note:</b> Adverse reactions increase significantly with doses above 3 mg/day.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9612512\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=guanfacine-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Guanfacine: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>ADHD:</b> Extended release: Children &ge;6 years and Adolescents &le;17 years: Oral: Initial: 1 mg once daily; may adjust by increments of no more than 1 mg/week. Recommended target dose is 0.05 to 0.12 mg/kg/dose (1 to 7 mg) once daily, depending on clinical response and tolerability.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Maximum daily doses: Doses above the following have not been evaluated.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Monotherapy: Children 6 to 12 years: 4 mg/<b>day</b>; Adolescents: 13 to 17 years: 7 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adjunct therapy (with psychostimulants): 4 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">Suggested fixed target dose range for patients weighing &ge;25 kg: All doses administered once daily at the same time (either in the morning or evening) not to exceed age-based maximum daily doses.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">25 to 33.9 kg: 2 to 3 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">34 to 41.4 kg: 2 to 4 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">41.5 to 49.4 kg: 3 to 5 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">49.5 to 58.4 kg: 3 to 6 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">58.5 to 91 kg: 4 to 7 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">&gt;91 kg: 5 to 7 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:2em;\">\n      <b>Dosage adjustment for concomitant CYP3A4 inhibitors/inducers:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Strong CYP3A4 inhibitors:</i> If initiating guanfacine while taking a strong CYP3A4 inhibitor or if continuing guanfacine and adding a strong CYP3A4 inhibitor, decrease guanfacine dose by 50%. If continuing guanfacine and discontinuing the strong CYP3A4 inhibitor, increase guanfacine to the recommended dose.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Strong CYP3A4 inducers:</i> If initiating guanfacine while taking a strong CYP3A4 inducer, consider increasing guanfacine to double the recommended dose. If continuing guanfacine and adding a strong CYP3A4 inducer, consider increasing guanfacine gradually over 1 to 2 weeks to double the recommended dose. If continuing guanfacine and discontinuing the strong CYP3A4 inducer, gradually decrease guanfacine dose to the recommended dose over 1 to 2 weeks. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:2em;\">\n      <b>Conversion from immediate release to extended release:</b> Discontinue the immediate release formulation, and titrate according to extended release recommendations.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Missed doses of extended release:</b> If &ge;2 consecutive doses are missed, consider repeating dosage titration based on patient tolerability.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Discontinuation of extended release:</b> Gradually discontinue by tapering dose in decrements of &le;1 mg every 3 to 7 days to avoid rebound hypertension.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Hypertension:</b> Children &ge;12 years and Adolescents: Immediate release: Oral: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <b>Tourette syndrome (off-label use):</b>  Children &ge;6 years and Adolescents &le;16 years: Immediate release: Oral: Initial: 0.5 mg once daily at bedtime for 3 days, then 0.5 mg twice daily for 4 days, then 0.5 mg 3 times daily; may further increase dose after 7 days based on clinical response to maximum daily dose of 4 mg/day in 3 divided doses (Scahill 2001); twice daily dosing may be effective for some patients (Chappell, 1995; Cummings 2002). <b>Note:</b> Limited data available; greater efficacy shown in patients with ADHD comorbidity (AACAP [Murphy 2013]; ESSTS [Roessner 2011]; Pringsheim 2012; Weisman 2013).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178171\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Immediate release: Refer to adult dosing. In the management of hypertension, consider lower initial doses and titrate to response (Aronow 2011).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9612513\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Immediate release: Children &ge;12 years, Adolescents, and Adults: There are no specific dosage adjustments provided in the manufacturer&rsquo;s labeling; however, the lower end of the dosing range is recommended in patients with renal impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Extended release: Children &ge;6 years and Adolescents &le;17 years: There are no dosage adjustments provided in the manufacturer&rsquo;s labeling (has not been studied); however, dosage adjustments may be necessary in patients with significant renal impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hemodialysis: Immediate release or extended release: Dialysis clearance is low (~15% of total clearance).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9612514\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Immediate release: Children &ge;12 years, Adolescents, and Adults: There are no dosage adjustments provided in the manufacturer&rsquo;s labeling; however, use with caution in chronic hepatic impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Extended release: Children &ge;6 years and Adolescents &le;17 years: There are no dosage adjustments provided in the manufacturer&rsquo;s labeling (has not been studied); however, dosage adjustments may be necessary in patients with significant hepatic impairment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178152\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Tenex: 1 mg [DSC] [contains fd&amp;c red #40 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Tenex: 2 mg [DSC] [contains fd&amp;c yellow #10 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 1 mg, 2 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Extended Release 24 Hour, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Intuniv: 1 mg, 2 mg, 3 mg, 4 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 1 mg, 2 mg, 3 mg, 4 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178139\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45501794\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US. Refer also to Dosage forms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablet Extended Release 24 Hour, Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Intuniv XR: 1 mg, 2 mg, 3 mg, 4 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9612516\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Immediate-release tablets are usually given at bedtime to minimize somnolence. Extended-release tablets should be taken at the same time each day (either morning or evening), and should not be crushed, broken, or chewed. Do not administer ER tablets with a  high-fat meal because of increased exposure. Formulations (immediate release versus extended release) are not interchangeable.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178153\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Attention-deficit/hyperactivity disorder (extended release only):</b> Treatment of attention-deficit/hyperactivity disorder (ADHD) as monotherapy and as adjunctive therapy to stimulant medications.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hypertension (immediate release only):</b> Management of hypertension.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25725971\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Tourette syndrome (children and adolescents)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178195\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">GuanFACINE may be confused with guaiFENesin, guanabenz, guanidine</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Intuniv may be confused with Invega</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Tenex may be confused with Entex, Xanax</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Geriatric Patients: High-Risk Medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Beers Criteria: Guanfacine is identified in the Beers Criteria as a potentially inappropriate medication to be avoided in patients 65 years and older (independent of diagnosis or condition) due to high risk of CNS adverse effects and risk of bradycardia and orthostatic hypotension associated with central alpha blockers; not recommended as routine treatment for hypertension (Beers Criteria [AGS 2015]).</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Pharmacy Quality Alliance (PQA): Guanfacine is identified as a high-risk medication in patients 65 years and older on the PQA&rsquo;s, Use of High-Risk Medications in the Elderly (HRM) performance measure, a safety measure used by the Centers for Medicare and Medicaid Services (CMS) for Medicare plans.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Tenex [U.S.] may be confused with Kinex brand name for biperiden [Mexico]</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178146\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Drowsiness (10% to 57%; dose-related), headache (4% to 28%), fatigue (5% to 22%), dizziness (4% to 16%; dose-related), insomnia (2% to 13%),</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Xerostomia (3% to 54%; dose-related), abdominal pain (&le;8% to 19%; dose-related), decreased appetite (5% to 15%), constipation (2% to 15%; dose-related)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Hypotension (&le;1% to 9%; dose-related; includes orthostatic), bradycardia (2% to 5%), atrioventricular block (&ge;2%), sinus arrhythmia (&ge;2%), syncope (1% to &ge;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Irritability (5% to 8%), lethargy (3% to 8%), anxiety (2% to 5%), nightmares (3% to 4%), emotional lability (children and adolescents 6 to 17 years: 2% to 3%), agitation (&ge;2%), depression (&ge;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Skin rash (2% to 3%), pruritus (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Weight gain (&le;2% to 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (&le;5% to 7%), vomiting (2% to 7%), diarrhea (2% to 6%), dyspepsia (&ge;2%), stomach pain (&ge;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Impotence (&le;3% to 7%), urinary incontinence (2% to 5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Weakness (&le;2% to 7%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Asthma (&ge;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever (8%; Biederman 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Frequency not defined:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Chest pain, hypertension</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Seizure</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Pallor</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Urinary frequency</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Increased serum ALT</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hypersensitivity: Hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Abnormal hepatic function tests, aggressive behavior (immediate release; children), alopecia, amnesia, arthralgia, blurred vision, cardiac fibrillation, cerebrovascular accident, confusion, conjunctivitis, decreased libido, dermatitis, diaphoresis, dysgeusia, dysphagia, dyspnea, edema, exacerbation of cardiac disease (sinus node dysfunction, atrioventricular block), exfoliative dermatitis, hallucination, hypertensive encephalopathy (with abrupt discontinuation), hypokinesia, iritis, leg cramps, leg pain, malaise, mania (immediate release; children), myalgia, myocardial infarction, nervousness, nocturia, palpitations, paresis, paresthesia, purpura, Raynaud phenomenon, rebound hypertension, renal failure, rhinitis, tachycardia, tinnitus, tremor, vertigo, visual disturbance</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178156\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to guanfacine or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178143\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular effects: May cause atrioventricular (AV) block, bradycardia, hypotension, orthostasis, sinus node dysfunction, and syncope; these effects are dose-dependent, more pronounced during the first month of therapy, or may worsen especially when used with other sympatholytic drugs. Monitor vital signs frequently in patients with cardiac conduction abnormalities or those concomitantly treated with other sympatholytic drugs.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS effects: May cause sedation and drowsiness which may impair physical or mental abilities; patients must be cautioned about performing tasks that require mental alertness (eg, operating machinery, driving).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Dermatological effects: Skin rash with exfoliation and pruritus have been reported; discontinue guanfacine and monitor patients who develop a rash.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Use with caution in patients with severe coronary insufficiency, recent MI, or a history of bradycardia, cardiovascular disease, heart block, hypotension, or syncope. Cautious use is also recommended in patients with conditions that predispose them to syncope (eg, orthostasis, dehydration).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cerebrovascular disease: Use with caution in patients with cerebrovascular disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with chronic hepatic impairment. Dosage adjustment may be necessary in severe impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with chronic renal impairment. Dosage adjustment may be necessary in severe impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Product interchangeability: Formulations of guanfacine (immediate release versus extended release) are not interchangeable on a mg to mg basis because bioavailability, C<sub>max</sub>, and T<sub>max</sub> vary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Discontinuation of therapy: Increased heart rate and rebound hypertension have been reported with abrupt discontinuation; hypertensive encephalopathy has also been reported. Increased risk of rebound hypertension may occur in children with GI illnesses and vomiting. Concomitant stimulant use may increase blood pressure if guanfacine is abruptly stopped. To minimize these effects, taper the dose in decrements of &le;1 mg every 3 to 7 days and monitor blood pressure and pulse following dosage reduction/discontinuation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; ADHD treatment: Appropriate use: Recommended to be used as part of a comprehensive treatment program for attention-deficit disorders; safety and efficacy of long-term use for the treatment of ADHD (&gt;2 years) have not been established (Sallee 2009).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9837647\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178147\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8510&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alcohol (Ethyl): May enhance the CNS depressant effect of GuanFACINE.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, blood pressure lowering medications should be withheld for 24 hours prior to amifostine administration. If blood pressure lowering therapy cannot be withheld, amifostine should not be administered.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amphetamines: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Beta-Blockers: Alpha2-Agonists may enhance the AV-blocking effect of Beta-Blockers. Sinus node dysfunction may also be enhanced. Beta-Blockers may enhance the rebound hypertensive effect of Alpha2-Agonists. This effect can occur when the Alpha2-Agonist is abruptly withdrawn.  Management: Closely monitor heart rate during treatment with a beta blocker and clonidine. Withdraw beta blockers several days before clonidine withdrawal when possible, and monitor blood pressure closely. Recommendations for other alpha2-agonists are unavailable.<b> Exceptions: </b>Levobunolol; Metipranolol.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bradycardia-Causing Agents: May enhance the bradycardic effect of other Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bretylium: May enhance the bradycardic effect of Bradycardia-Causing Agents. Bretylium may also enhance atrioventricular (AV) blockade in patients receiving AV blocking agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brigatinib: May diminish the antihypertensive effect of Antihypertensive Agents. Brigatinib may enhance the bradycardic effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromopride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol. Bromperidol may diminish the hypotensive effect of Blood Pressure Lowering Agents. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine patches (Butrans brand) at 5 mcg/hr in adults when used with other CNS depressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabis: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: Bradycardia-Causing Agents may enhance the bradycardic effect of Ceritinib.  Management: If this combination cannot be avoided, monitor patients for evidence of symptomatic bradycardia, and closely monitor blood pressure and heart rate during therapy.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Conivaptan: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Moderate): May decrease the serum concentration of GuanFACINE. Management: Increase the guanfacine dose by up to double when initiating concomitant therapy with moderate CYP3A4 inducers. Increase guanfacine dose gradually over 1-2 weeks if moderate CYP3A4 inducer therapy is just beginning.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Strong): May decrease the serum concentration of GuanFACINE. Management: Increase the guanfacine dose by up to double when initiating concomitant therapy with strong CYP3A4 inducers. Increase guanfacine dose gradually over 1-2 weeks if strong CYP3A4 inducer therapy is just beginning.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Moderate): May increase the serum concentration of GuanFACINE. Management: Reduce the guanfacine dose by 50% when initiating this combination.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Strong): May increase the serum concentration of GuanFACINE. Management: Reduce the guanfacine dose by 50% when initiating this combination.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabrafenib: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Seek alternatives to the CYP3A4 substrate when possible.  If concomitant therapy cannot be avoided, monitor clinical effects of the substrate closely (particularly therapeutic effects).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dasatinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Doxylamine: May enhance the CNS depressant effect of CNS Depressants. Management: The manufacturer of Diclegis (doxylamine/pyridoxine), intended for use in pregnancy, specifically states that use with other CNS depressants is  not recommended.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dronabinol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Enzalutamide: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Concurrent use of enzalutamide with CYP3A4 substrates that have a narrow therapeutic index should be avoided.  Use of enzalutamide and any other CYP3A4 substrate should be performed with caution and close monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosaprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Hypotensive Properties): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HYDROcodone: CNS Depressants may enhance the CNS depressant effect of HYDROcodone.  Management: Avoid concomitant use of hydrocodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Idelalisib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iobenguane I 123: Alpha2-Agonists may diminish the therapeutic effect of Iobenguane I 123. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ivabradine: Bradycardia-Causing Agents may enhance the bradycardic effect of Ivabradine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Kava Kava: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lacosamide: Bradycardia-Causing Agents may enhance the AV-blocking effect of Lacosamide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Levodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lofexidine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methylphenidate: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Minocycline: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mirtazapine: May diminish the antihypertensive effect of Alpha2-Agonists. Management: Consider avoiding concurrent use.  If the combination cannot be avoided, monitor for decreased effects of alpha2-agonists if mirtazapine is initiated/dose increased, or increased effects if mirtazapine is discontinued/dose decreased.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mitotane: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Doses of CYP3A4 substrates may need to be adjusted substantially when used in patients being treated with mitotane.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nabilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Opioid Analgesics: CNS Depressants may enhance the CNS depressant effect of Opioid Analgesics.  Management: Avoid concomitant use of opioid analgesics and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oxomemazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE.  Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palbociclib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Piribedil: CNS Depressants may enhance the CNS depressant effect of Piribedil. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pitolisant: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Combined use of pitolisant with a CYP3A4 substrate that has a narrow therapeutic index should be avoided. Other CYP3A4 substrates should be monitored more closely when used with pitolisant.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ruxolitinib: May enhance the bradycardic effect of Bradycardia-Causing Agents. Management: Ruxolitinib Canadian product labeling recommends avoiding use with bradycardia-causing agents to the extent possible.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sarilumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Serotonin/Norepinephrine Reuptake Inhibitors: May diminish the antihypertensive effect of Alpha2-Agonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Siltuximab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Simeprevir: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">St John's Wort: May decrease the serum concentration of GuanFACINE. Management: Consider increasing the guanfacine dose by 2-fold when adding St Johns Wort.  Titrate the guanfacine dose up to a max of 8 mg/day when starting guanfacine in a patient who is taking St Johns Wort.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Stiripentol: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of stiripentol with CYP3A4 substrates that are considered to have a narrow therapeutic index should be avoided due to the increased risk for adverse effects and toxicity.  Any CYP3A4 substrate used with stiripentol requires closer monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant.  Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary.  Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tapentadol: May enhance the CNS depressant effect of CNS Depressants. Management: Avoid concomitant use of tapentadol and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Terlipressin: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetrahydrocannabinol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tricyclic Antidepressants: May diminish the antihypertensive effect of Alpha2-Agonists.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trimeprazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Valproate Products: GuanFACINE may increase the serum concentration of Valproate Products. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Yohimbine: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for  men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45501431\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Grapefruit juice/products: Because of potential inhibition of CYP3A4-mediated metabolism of guanfacine, the Canadian labeling recommends avoiding use of these products during therapy with guanfacine.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178148\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9612487\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have not been observed in animal reproduction studies except in doses that also caused maternal toxicity. Information related to guanfacine use during pregnancy is limited (Philipp 1980). Untreated chronic maternal hypertension is associated with adverse events in the fetus, infant, and mother. If treatment for hypertension during pregnancy is needed, other agents are preferred (ACOG 2012).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16265811\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if guanfacine is excreted in breast milk. The manufacturer recommends that caution be exercised when administering guanfacine to nursing women.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9612515\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Extended-release tablets: Do not administer with a high-fat meal due to increased exposure.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6012534\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Heart rate, blood pressure; rebound hypertension (with abrupt discontinuation)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">When used for the treatment of ADHD, thoroughly evaluate for cardiovascular risk. Monitor heart rate, blood pressure (prior to initiation, following dosage adjustments, and periodically thereafter), and consider obtaining ECG prior to initiation (Vetter 2008).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178142\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Guanfacine is a selective alpha<sub>2A</sub>-adrenoreceptor agonist that reduces sympathetic nerve impulses, resulting in reduced sympathetic outflow and a subsequent decrease in vasomotor tone and heart rate.  In addition, guanfacine preferentially binds postsynaptic alpha<sub>2A</sub>-adrenoreceptors in the prefrontal cortex and has been theorized to improve delay-related firing of prefrontal cortex neurons. As a result, underlying working memory and behavioral inhibition are affected; thereby improving symptoms associated with ADHD.  Guanfacine is not a CNS stimulant. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178155\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">\n      <b>Note: </b>When dosed at same mg dose, the extended-release product has a lower peak serum concentration (60% lower) and AUC (43% lower) compared with the immediate-release formulation. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Readily absorbed.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration: Antihypertensive effect: 24 hours following single dose </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Immediate release: 6.3 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Extended release: V<sub>d</sub> (apparent): Children &ge;6 years: 23.7 L/kg; Adolescent: 19.9 L/kg (Boellner 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: ~70%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic via CYP3A4. Approximately 50% of clearance is hepatic.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Immediate release: ~80%</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Extended release (relative to immediate release): 58%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Immediate release: ~17 hours (range: 10 to 30 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Extended release: Children &ge;6 years: 14.4 hours; Adolescents: 18 hours (Boellner 2007); Adults: 16 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Immediate release: 2.6 hours (range: 1 to 4 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Extended release: Children &ge;6 years and Adolescents: 5 hours (Boellner 2007); Adults: 4 to 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (~50%  [40% to 75% of dose] as unchanged drug)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178159\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, 24-hour</b> (GuanFACINE HCl ER Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg (100): $1,049.11</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 mg (100): $1,049.11</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">3 mg (100): $1,049.11</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 mg (100): $1,049.11</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, 24-hour</b> (Intuniv Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg (100): $1,165.68</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 mg (100): $1,165.68</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">3 mg (100): $1,165.68</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 mg (100): $1,165.68</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (GuanFACINE HCl Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg (100): $87.20</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 mg (100): $117.60</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178160\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Dipresan (HR);</li>\n      <li>Estulic (BE, BF, BJ, CH, CI, CZ, DE, ET, FR, GH, GM, GN, HN, HU, ID, JP, KE, LR, MA, ML, MR, MU, MW, NE, NG, NL, PH, RU, SC, SD, SL, SN, TN, TZ, UG, ZA, ZM, ZW);</li>\n      <li>Estulik (UA);</li>\n      <li>Hipertensal (AR);</li>\n      <li>Intuniv (IE, JP)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists (ACOG), &quot;ACOG Practice Bulletin No. 125: Chronic Hypertension in Pregnancy,&quot; <i>Obstet Gynecol</i>, 2012, 119(2 Pt 1):396-407.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/guanfacine-drug-information/abstract-text/22270315/pubmed\" target=\"_blank\" id=\"22270315\">22270315</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American Geriatrics Society 2015 updated Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2015;63(11):2227-2246. doi:10.1111/jgs.13702.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/guanfacine-drug-information/abstract-text/26446832/pubmed\" target=\"_blank\" id=\"26446832\">26446832</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronow WS, Fleg JL, Pepine CJ, et al, &ldquo;ACCF/AHA 2011 Expert Consensus Document on Hypertension in the Elderly: A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents,&rdquo; <i>Circulation</i>, 2011, 123(21):2434-506.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/guanfacine-drug-information/abstract-text/21518977/pubmed\" target=\"_blank\" id=\"21518977\">21518977</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bassarath L, &quot;Medication Strategies in Childhood Aggression: A Review,&quot; <i>Can J Psychiatry</i>, 2003, 48(6):367-73.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/guanfacine-drug-information/abstract-text/12894610/pubmed\" target=\"_blank\" id=\"12894610\">12894610</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Biederman J, Melmed RD, Patel A, et al, &ldquo;A Randomized, Double-Blind, Placebo-Controlled Study of Guanfacine Extended Release in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder,&rdquo; <i>Pediatrics</i>, 2008, 121(1):e73-84.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/guanfacine-drug-information/abstract-text/18166547/pubmed\" target=\"_blank\" id=\"18166547\">18166547</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Biederman J, Melmed RD, Patel A, et al, &quot;Long-Term, Open-Label Extension Study of Guanfacine Extended Release in Children and Adolescents With ADHD,&quot; <i>CNS Spectr</i>, 2008, 13(12):1047-55.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/guanfacine-drug-information/abstract-text/19179940/pubmed\" target=\"_blank\" id=\"19179940\">19179940</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Boellner SW, Pennick M, Fiske K, et al, &quot;Pharmacokinetics of a Guanfacine Extended-Release Formulation in Children and Adolescents With Attention-Deficit-Hyperactivity Disorder,&quot; <i>Pharmacotherapy</i>, 2007, 27(9):1253-62.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/guanfacine-drug-information/abstract-text/17723079/pubmed\" target=\"_blank\" id=\"17723079\">17723079</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chappell PB, Riddle MA, Scahill L, et al, Guanfacine Treatment of Comorbid Attention-Deficit Hyperactivity Disorder and Tourette's Syndrome: Preliminary Clinical Experience,&quot; <i>J Am Acad Child Adolesc Psychiatry</i>, 1995, 34(9):1140-6.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cummings DD, Singer HS, Krieger M, Miller TL, Mahone EM. Neuropsychiatric effects of guanfacine in children with mild tourette syndrome: a pilot study. <i>Clin Neuropharmacol</i>. 2002;25(6):325-332.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/guanfacine-drug-information/abstract-text/12469007/pubmed\" target=\"_blank\" id=\"12469007\">12469007</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Funder JW, Carey RM, Mantero F, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society Clinical Practice Guideline. <i>J Clin Endocrinol Metab</i>. 2016;101(5):1889-1916. doi: 10.1210/jc.2015-4061.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/guanfacine-drug-information/abstract-text/26934393/pubmed\" target=\"_blank\" id=\"26934393\">26934393</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Go AS, Bauman M, King SM, et al. An effective approach to high blood pressure control: a science advisory from the American Heart Association, the American College of Cardiology, and the Centers for Disease Control and Prevention [published online November 15, 2013]. <i>Hypertension</i>.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/guanfacine-drug-information/abstract-text/24243703/pubmed\" target=\"_blank\" id=\"24243703\">24243703</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Intuniv (guanfacine) [prescribing information]. Lexington, MA: Shire US Inc; November 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Intuniv XR (guanfacine) [product monograph]. Toronto, Ontario, Canada: Shire Canada Inc; November 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kaplan NM and Sever PS, &ldquo;Combination Therapy: A Key to Comprehensive Patient Care,&rdquo; <i>Am J Hypertens</i>, 1997, 10(7 Pt 2):127S.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/guanfacine-drug-information/abstract-text/9231887/pubmed\" target=\"_blank\" id=\"9231887\">9231887</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Moser M and Black HR, &ldquo;The Role of Combination Therapy in the Treatment of Hypertension,&rdquo; <i>Am J Hypertens</i>, 1998, 11(6 Pt 2):73S-8S, 95S-100S.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/guanfacine-drug-information/abstract-text/9655566/pubmed\" target=\"_blank\" id=\"9655566\">9655566</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Murphy TK, Lewin AB, Storch EA, Stock S; American Academy of Child and Adolescent Psychiatry (AACAP) Committee on Quality Issues (CQI). Practice parameter for the assessment and treatment of children and adolescents with tic disorders. <i>J Am Acad Child Adolesc Psychiatry</i>. 2013;52(12):1341-1359.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/guanfacine-drug-information/abstract-text/24290467/pubmed\" target=\"_blank\" id=\"24290467\">24290467</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Perrin JM, Friedman RA, Knilans TK; Black Box Working Group; Section on Cardiology and Cardiac Surgery. Cardiovascular monitoring and stimulant drugs for attention-deficit/hyperactivity disorder. <i>Pediatrics</i>. 2008;122(2):451-453.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/guanfacine-drug-information/abstract-text/18676566/pubmed\" target=\"_blank\" id=\"18676566\">18676566</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pharmacy Quality Alliance. Use of high-risk medications in the elderly (HRM). http://pqaalliance.org/images/uploads/files/HRM2015.pdf. Published 2015. Accessed October 26, 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Philipp E, &quot;Guanfacine in the Treatment of Hypertension Due to Pre-eclamptic Toxaemia in Thirty Women,&quot; <i>Br J Clin Pharmacol</i>, 1980, 10(Suppl 1):137-40.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/guanfacine-drug-information/abstract-text/6994768/pubmed\" target=\"_blank\" id=\"6994768\">6994768</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pringsheim T, Doja A, Gorman D, et al. Canadian guidelines for the evidence-based treatment of tic disorders: pharmacotherapy. <i>Can J Psychiatry</i>. 2012;57(3):133-143.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/guanfacine-drug-information/abstract-text/22397999/pubmed\" target=\"_blank\" id=\"22397999\">22397999</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Roessner V, Plessen KJ, Rothenberger A, et al; ESSTS Guidelines Group. European clinical guidelines for Tourette syndrome and other tic disorders. Part II: pharmacological treatment. <i>Eur Child Adolesc Psychiatry</i>. 2011;20(4):173-196.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/guanfacine-drug-information/abstract-text/21445724/pubmed\" target=\"_blank\" id=\"21445724\">21445724</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sallee FR, Lyne A, Wigal T, et al, &ldquo;Long-Term Safety and Efficacy of Guanfacine Extended Release in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder,&rdquo; <i>J Child Adolesc Psychopharmacol</i>, 2009, 19(3):215-26.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/guanfacine-drug-information/abstract-text/19519256/pubmed\" target=\"_blank\" id=\"19519256\">19519256</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sallee FR, McGough J, Wigal T, et al, &ldquo;Guanfacine Extended Release in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder: A Placebo-Controlled Trial,&rdquo; <i>J Am Acad Child Adolesc Psychiatry</i>, 2009, 48(2):155-65.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/guanfacine-drug-information/abstract-text/19106767/pubmed\" target=\"_blank\" id=\"19106767\">19106767</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Scahill L, Chappell PB, Kim YS, et al. A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder. <i>Am J Psychiatry</i>. 2001;158(7):1067-1074.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/guanfacine-drug-information/abstract-text/11431228/pubmed\" target=\"_blank\" id=\"11431228\">11431228</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vetter VL, Elia J, Erickson CH, et al; American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee; American Heart Association Council on Cardiovascular Nursing. Cardiovascular monitoring of children and adolescents with heart disease receiving medications for attention deficit/hyperactivity disorder [corrected]: a scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing. <i>Circulation</i>. 2008;117(18):2407-2423.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/guanfacine-drug-information/abstract-text/18427125/pubmed\" target=\"_blank\" id=\"18427125\">18427125</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Weisman H, Qureshi IA, Leckman JF, Scahill L, Bloch MH. Systematic review: pharmacological treatment of tic disorders--efficacy of antipsychotic and alpha-2 adrenergic agonist agents. <i>Neurosci Biobehav Rev</i>. 2013;37(6):1162-1171.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/guanfacine-drug-information/abstract-text/23099282/pubmed\" target=\"_blank\" id=\"23099282\">23099282</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8510 Version 216.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F178166\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F21313111\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F178189\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F178170\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F9612512\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F178171\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F9612513\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F9612514\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F178152\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F178139\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F45501794\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F9612516\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F178153\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25725971\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F178195\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F178146\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F178156\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F178143\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F9837647\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F178147\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F45501431\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F178148\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F9612487\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F16265811\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F9612515\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F6012534\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F178142\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F178155\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F178159\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F178160\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8510|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=guanfacine-patient-drug-information\" class=\"drug drug_patient\">Guanfacine: Patient drug information</a></li><li><a href=\"topic.htm?path=guanfacine-pediatric-drug-information\" class=\"drug drug_pediatric\">Guanfacine: Pediatric drug information</a></li></ul></div></div>","javascript":null}